Bluebird, Celgene to co-develop anti-BCMA CAR T cell therapy for multiple myeloma

This article was originally published here

bluebird bio and Celgene have agreed to co-develop and co-promote bb2121, an investigational anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy for the potential treatment of relapsed/refractory multiple myeloma in the US.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply